Galapagos: FY results and termination of Roche alliance could provide buying opportunity

BUY, Fair Value EUR22.5 (+10%)

News published on March Friday 8, 2013
Share on

Galapagos released full-year results this morning which met expectations adjusted for pulled forward investment for GLPG0634 (JAK-1 with AbbVie). Guidance for 2013 is EUR160m and further visibility is expected during the year for other items such as net result or cash position. Galapagos also announced the end of the Roche alliance in fibrosis due to an internal strategic decision at Roche. Should the stock be under pressure today, we would use any weakness to buy as Galapagos remains one of our top-picks.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities